Imunon Inc (IMNN)vsVertex Pharmaceuticals Inc (VRTX)
IMNN
Imunon Inc
$1.54
+0.65%
HEALTHCARE · Cap: $6.35M
VRTX
Vertex Pharmaceuticals Inc
$481.70
-0.34%
HEALTHCARE · Cap: $119.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 9774300% more annual revenue ($12.22B vs $125,000). VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX appears more attractively valued with a PEG of 1.63. VRTX earns a higher WallStSmart Score of 68/100 (B-).
IMNN
Avoid25
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IMNN.
Margin of Safety
+49.1%
Fair Value
$941.26
Current Price
$481.70
$459.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IMNN
The strongest argument for IMNN centers on Debt/Equity, Price/Book.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : IMNN
The primary concerns for IMNN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
IMNN profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
IMNN carries more volatility with a beta of 1.95 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 25/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Imunon Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Imunon Inc. is a clinical-stage biotechnology company at the forefront of developing innovative immune-mediated therapies targeting cancer and infectious diseases. Leveraging its proprietary INFECT platform, Imunon aims to enhance immune response mechanisms, facilitating effective tumor eradication. With a diversified pipeline of therapeutics across multiple clinical stages and strategic collaborations that bolster its operational expertise, Imunon is strategically positioned to revolutionize immunotherapy, offering the potential to significantly enhance treatment outcomes for patients while shaping the future of the biopharmaceutical landscape.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?